It was originally developed for the treatment of primary biliary cholangitis [48] and is currently in the most advanced stage being tested for NASH in several clinical trials with evidence of significant alleviation of plasma liver ALT and AST levels and mild improvement in steatosis, hepatic ballooning, lobular inflammation and fibrosis [49]. This evidence concerns the gene GPT and steatosis.